dr. Mravik Andras,Virag Attila,dr. Nagy Tamas,dr. Volk Balazs,Kovacs Jozsef,Kataine Fadgyas Katalin,dr. Halasz Judit,Tothne Dr. Lauritz Maria,Janine Vakulya Gabriella,Varga Zoltan
申请号：
HU1600051
公开号：
HU1600051A2
申请日:
2016.02.01
申请国别(地区):
HU
年份:
2017
代理人:
摘要：
The subject of the present invention is the cocrystal form of (R)-2-(2-aminothiazol-4-yl)-4'- {2-[(2-hydroxy-2-phenyl)ethylamino]ethyl}acetamide (mirabegron) of formula (1) and halide salt of an alkaline earth metal or halide salt of a d-yield metal and its solvates, where the alkaline earth metal is preferably calcium or magnesium and the d-yield metal is preferably zinc. The more specific subject of the present invention is the cocrystal form of mirabegron of formula (2) consisting of 2 molecules of mirabegron, 1 molecule of magnesium-chloride (MgC2) and 2 molecules of water (H2O), its preparation method, a pharmaceutical composition comprising the cocrystal of formula (2) and the therapeutical use of the latter pharmaceutical composition.
